Longeveron (LGVN) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
8 Jul, 2026Opening remarks and agenda
Chair welcomed shareholders to the third annual meeting, emphasizing virtual participation and support.
Stockholders were informed about the process for submitting questions and the meeting's adherence to company bylaws.
Executive officers and independent auditors were introduced, with auditors available for questions.
Board and executive committee updates
Four Class III director nominees were presented for election to serve three-year terms expiring in 2027.
No additional nominations were received before the deadline, closing the nominations.
Shareholder proposals
Proposal to elect four directors for three-year terms.
Proposal to amend the 2021 Incentive Award Plan to increase shares available for issuance.
Proposal to ratify Marcum LLP as independent auditors for the fiscal year ending December 31, 2024.
Latest events from Longeveron
- All proposals, including director elections and share amendments, were approved by majority vote.LGVN
AGM 202615 Jul 2026 - Revenue up 177% and pivotal trials advanced, but more funding may be needed for late-stage work.LGVN
Q3 20248 Jul 2026 - Key proposals include director elections, share increases, and a reverse stock split to maintain listing.LGVN
Proxy filing20 May 2026 - Virtual meeting to vote on directors, capital changes, and auditor, with online proxy access.LGVN
Proxy filing20 May 2026 - Net loss narrowed to $4.7M in Q1 2026, but future operations require new funding and partnerships.LGVN
Q1 202619 May 2026 - Capital-light strategy and licensing focus position laromestrocel for major value inflection in 2026.LGVN
Investor presentation13 May 2026 - Annual meeting covers director elections, share structure changes, incentive plan, and auditor ratification.LGVN
Proxy filing5 May 2026 - HLHS Phase 2b data and PRV eligibility position laromestrocel for major value inflection.LGVN
Investor presentation4 May 2026 - Biotech registers resale of shares amid financial uncertainty and ongoing clinical development.LGVN
Registration filing10 Apr 2026